January 19, 2021

J&J’s single-dose COVID-19 vaccine has good safety profile

By: Judy Mathias

Editor's Note

Results from Johnson & Johnson’s early-stage trials for its COVID-19 vaccine showed neutralizing antibodies in all participants who received the vaccine when they were tested at 57 days.

The J&J Ad26.COV2.S vaccine is different than the Pfizer-BioNTech and Moderna vaccines in that it is anenovirus-based rather than mRNA-based.

Sponsored Message

Though the other two COVID-19 vaccines require two doses, a single dose of J&J’s vaccine elicited a strong humoral response in a majority of vaccine recipients, with the presence of S-binding and neutralizing antibodies in more than 90% of participants, regardless of age or vaccine dose (ie, high or low).

In addition, during 71 days of follow-up after the first dose, antibody titers further increased and stabilized, which suggests the durability of the vaccine-elicited immune response.

Of the 805 participants, the most frequent adverse events were fatigue, headache, myalgia, and injection-site pain.

The interim analysis indicates that the Ad26.COV2.S vaccine is safe and immunogenic in both younger and older adults after a single vaccination with either the low or high dose, the researchers say.

The company hopes to launch the vaccine by March with a goal of delivering 1 billion doses this year.


Sign Up For OR a.m.
Sign up for the free OR a.m. eLetter to get news like this in your inbox every morning!

OR Manager Jobs
Live chat by BoldChat